Acute diabetes moderates trafficking of cardiac lipoprotein lipase through p38 mitogen-activated protein kinase-dependent actin cytoskeleton organization

Diabetes

Volumn 57, Issue 1, 2008, Pages 64-76

  Kim, Min Suk ^a   Kewalramani, Girish ^a   Puthanveetil, Prasanth ^a   Lee, Vivian ^a   Kumar, Ujendra ^a   An, Ding ^a   Abrahani, Ashraf ^a   Rodrigues, Brian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 AMINOIMIDAZOLE 4 CARBOXYAMIDE 1 BETA DEXTRO RIBOFURANOSIDE; CYTOCHALASIN D; DIAZOXIDE; F ACTIN; HEAT SHOCK PROTEIN 25; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPOPROTEIN LIPASE; MITOGEN ACTIVATED PROTEIN KINASE P38; THROMBIN; UNCLASSIFIED DRUG; ACTIN; FATTY ACID; SMALL INTERFERING RNA; TRIOLEIN;

ACTIN POLYMERIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RISK; CELL SURFACE; CONTROLLED STUDY; CYTOSKELETON; DIABETES MELLITUS; ENZYME ACTIVITY; FATTY ACID METABOLISM; HEART MUSCLE CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RAT; ANIMAL; CELL NUCLEUS; CORONARY BLOOD VESSEL; ENZYMOLOGY; GENE SILENCING; GENETICS; HEART MUSCLE; HEART VENTRICLE; METABOLISM; ULTRASTRUCTURE;

ACTINS; ANIMALS; CELL NUCLEUS; CORONARY VESSELS; CYTOSKELETON; DIAZOXIDE; FATTY ACIDS; GENE SILENCING; HEART VENTRICLES; LIPOPROTEIN LIPASE; MYOCARDIUM; MYOCYTES, CARDIAC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RNA, SMALL INTERFERING; TRIOLEIN;

EID: 38449096808     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-0832     Document Type: Article

References (57)

1. Stamler J, Vaccaro O, Neaton JD, et al.: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
2. Wilson PW: Diabetes mellitus and coronary heart disease. Endocrinol Metab Clin North Am 30:857- 881, 2001
3. Bertoni AG, Tsai A, Kasper EK, et al.: Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 26:2791-2795, 2003
4. Diamant M, Lamb HJ, Groeneveld Y, et al.: Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42:328-335, 2003
5. Fein FS: Diabetic cardiomyopathy. Diabetes Care 13:1169-1179, 1990
6. Fang ZY, Prins JB, Marwick TH: Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25:543-567, 2004
7. Rodrigues B, Cam MC, McNeill JH: Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27:169-179, 1995
8. Golfman LS, Takeda N, Dhalla NS: Cardiac membrane Ca(2+)-transport in alloxan-induced diabetes in rats. Diabetes Res Clin Pract 31 (Suppl.):S73-S77, 1996
9. Lopaschuk GD: Metabolic abnormalities in the diabetic heart. Heart Fail Rev 7:149-159, 2002
10. Yagyu H, Chen G, Yokoyama M, et al.: Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111:419-426, 2003
11. Chiu HC, Kovacs A, Blanton RM, et al.: Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96:225-233, 2005
12. Finck BN, Lehman JJ, Leone TC, et al.: The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109:121-130, 2002
13. Chiu HC, Kovacs A, Ford DA, et al.: A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107:813-822, 2001
14. Belke DD, Larsen TS, Gibbs EM, et al.: Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 279:E1104-E1113, 2000
15. Eckel RH: Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320:1060-1068, 1989
16. Pillarisetti S, Paka L, Sasaki A, et al.: Endothelial cell heparanase modulation of lipoprotein lipase activity: evidence that heparan sulfate oligosaccharide is an extracellular chaperone. J Biol Chem 272:15753-15759, 1997
17. Augustus AS, Kako Y, Yagyu H, et al.: Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab 284:E331-E339, 2003
18. Teusink B, Voshol PJ, Dahlmans VE, et al.: Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 52:614-620, 2003
19. Mulder M, Lombardi P, Jansen H, et al.: Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem 268:9369-9375, 1993
20. Hardie DG: Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144:5179-5183, 2003
21. An D, Pulinilkunnil T, Qi D, et al.: The metabolic "switch" AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am J Physiol Endocrinol Metab 288:E246-E253, 2005
22. Foy JM, Furman BL: Effect of single dose administration of diuretics on the blood sugar of alloxan-diabetic mice or mice made hyperglycaemic by the acute administration of diazoxide. Br J Pharmacol 47:124-132, 1973
23. Pulinilkunnil T, Qi D, Ghosh S, et al.: Circulating triglyceride lipolysis facilitates lipoprotein lipase translocation from cardiomyocyte to myocardial endothelial lining. Cardiovasc Res 59:788-797, 2003
24. Rodrigues B, Cam MC, Jian K, et al.: Differential effects of streptozotocin-induced diabetes on cardiac lipoprotein lipase activity. Diabetes 46:1346-1353, 1997
25. Sambandam N, Abrahani MA, St Pierre E, et al.: Localization of lipoprotein lipase in the diabetic heart: regulation by acute changes in insulin. Arterioscler Thromb Vasc Biol 19:1526-1534, 1999
26. Qi D, Kuo KH, Abrahani A, et al.: Acute intralipid infusion reduces cardiac luminal lipoprotein lipase but recruits additional enzyme from cardiomyocytes. Cardiovasc Res 72:124-133, 2006
27. Qi D, Pulinilkunnil T, An D, et al.: Single-dose dexamethasone induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. Diabetes 53:1790-1797, 2004
28. Pulinilkunnil T, Abrahani A, Varghese J, et al.: Evidence for rapid "metabolic switching" through lipoprotein lipase occupation of endothelial-binding sites. J Mol Cell Cardiol 35:1093-1103, 2003
29. Haugland RP, You W, Paragas VB, et al.: Simultaneous visualization of G-and F-actin in endothelial cells. J Histochem Cytochem 42:345-350, 1994
30. Pulinilkunnil T, An D, Ghosh S, et al.: Lysophosphatidic acid-mediated augmentation of cardiomyocyte lipoprotein lipase involves actin cytoskeleton reorganization. Am J Physiol Heart Circ Physiol 288:H2802-H2810, 2005
31. Kewalramani G, An D, Kim MS, et al.: AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes. J Mol Cell Cardiol 42:333-342, 2007
32. Li J, Miller EJ, Ninomiya-Tsuji J, et al.: AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ Res 97:872-879, 2005
33. Ewart HS, Severson DL: Insulin and dexamethasone stimulation of cardiac lipoprotein lipase activity involves the actin-based cytoskeleton. Biochem J 340:485-490, 1999
34. Zheng C, Lin Z, Zhao ZJ, et al.: MAPK-activated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and Hsp27. J Biol Chem 281:37215-37226, 2006
35. Camps L, Reina M, Llobera M, et al.: Lipoprotein lipase: cellular origin and functional distribution. Am J Physiol 258:C673-C681, 1990
36. Otarod JK, Goldberg IJ: Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr Atheroscler Rep 6:335-342, 2004
37. Hardie DG, Hawley SA: AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 23:1112-1119, 2001
38. Hardie DG, Carling D: The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 246:259-273, 1997
39. Hong SP, Leiper FC, Woods A, et al.: Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc Natl Acad Sci U S A 100:8839-8843, 2003
40. Hayashi T, Hirshman MF, Fujii N, et al.: Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism. Diabetes 49:527-531, 2000
41. Russell RR 3rd, Bergeron R, Shulman GI, et al.: Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 277:H643-H649, 1999
42. Marsin AS, Bertrand L, Rider MH, et al.: Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 10:1247-1255, 2000
43. Luiken JJ, Coort SL, Willems J, et al.: Contraction-induced fatty acid translocase/ CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 52:1627-1634, 2003
44. Kudo N, Barr AJ, Barr RL, et al.: High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270:17513-17520, 1995
45. Watt MJ, Steinberg GR, Chen ZP, et al.: Fatty acids stimulate AMP-activated protein kinase and enhance fatty acid oxidation in L6 myotubes. J Physiol 574:139-147, 2006
46. Wu Y, Song P, Xu J, et al.: Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 282:9777-9788, 2007
47. Tan Y, Rouse J, Zhang A, et al.: FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J 15:4629-4642, 1996
48. Dai T, Natarajan R, Nast CC, et al.: Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. Kidney Int 69:806-814, 2006
49. Corton JM, Gillespie JG, Hawley SA, et al.: 5-aminoimidazole-4- carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229:558-565, 1995
50. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR: Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 279:32771-32779, 2004
51. Chabowski A, Momken I, Coort SL, et al.: Prolonged AMPK activation increases the expression of fatty acid transporters in cardiac myocytes and perfused hearts. Mol Cell Biochem 288:201-212, 2006
52. Smith JL, Patil PB, Fisher JS: AICAR and hyperosmotic stress increase insulin-stimulated glucose transport. J Appl Physiol 99:877-883, 2005
53. Hilder TL, Baer LA, Fuller PM, et al.: Insulin-independent pathways mediating glucose uptake in hindlimb-suspended skeletal muscle. J Appl Physiol 99:2181-2188, 2005
54. Kanda Y, Watanabe Y: Thrombin-induced glucose transport via Src-p38 MAPK pathway in vascular smooth muscle cells. Br J Pharmacol 146:60-67, 2005
55. Levak-Frank S, Radner H, Walsh A, et al.: Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J Clin Invest 96:976-986, 1995
56. Augustus AS, Buchanan J, Park TS, et al.: Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 281:8716-8723, 2006
57. Neitzel AS, Carley AN, Severson DL: Chylomicron and palmitate metabolism by perfused hearts from diabetic mice. Am J Physiol Endocrinol Metab 284:E357-E365, 2003